Accepted for/Published in: JMIR Research Protocols
Date Submitted: Jul 6, 2020
Date Accepted: Nov 17, 2020
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
An autonomy-supportive online decision aid to assist smokers in choosing evidence-based cessation assistance: Development process & Protocol of a randomized controlled trial
ABSTRACT
Background:
Decision aids (DAs) may be used to facilitate an autonomous, informed decision to cease smoking and promote the uptake of evidence-based cessation assistance (i.e. behavioral support, nicotine replacement therapy and/or prescription medication). However, knowledge is lacking regarding their effective elements and (cost-)effectiveness.
Objective:
A fully automated online DA (called ‘VISOR’) that includes both an implicit and explicit value-clarification exercise was developed that helps smokers to choose evidence-based cessation assistance. This DA will be tested in a randomized controlled trial (RCT).
Methods:
The development of the DA ’VISOR’ was based on the International Patient Decision Aid Standards (IPDAS) guidelines. Viewpoints of both end users (collected through 20 interviews with current smokers) and clinical & scientific experts (assessed using a Delphi study with 24 scientists and 38 clinicians) were assessed regarding cessation tool decision making and preferred DA content. These findings, together with principles from the Self-Determination Theory, served as input for the development of the online DA. A first DA prototype was alpha tested in September 2019 and beta-tested (usability) in December 2019; feedback was incorporated and resulted in a final DA version. The DA combines intuitive and deliberate decision-making processes to facilitate both decision-making styles. An RCT will be conducted to assess the DA’s (cost-)-effectiveness. Within this RCT the DA will be compared to a DA that will not include the explicit value clarification exercise.
Results:
Data regarding the effect of the VISOR DA is currently being collected, expecting conclusion in 2021.
Conclusions:
By making use of an iterative process that integrated different stakeholders’ perspectives (including end users) we were able to systematically design an evidence-based DA. The effect of the DA on decision-making and smoking outcomes is currently being studied. Clinical Trial: The trial is registered in the Netherlands Trial Register (NL8270).
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.